Nollau P, Jung R, Neumaier M, Wagener C
Abteilung für Klinische Chemie, Medizinische Klinik, Universitètskrankenhaus Eppendorf, Hamburg, Germany.
Scand J Clin Lab Invest Suppl. 1995;221:116-21. doi: 10.3109/00365519509090575.
Tumour cells shed from solid primary tumours can be detected by the polymerase chain reaction (PCR) based on the selective amplification of mutated tumour genes or of genes expressed in a tissue specific manner. When tumour specific alterations are amplified, few tumour cells can be detected in excess of normal cells derived from the same tissue. Thus, malignant cells can be detected specifically in pancreatic juice, stool, urine, and sputum. Here we describe the adaptation of the mutant enriched PCR in conjunction with the introduction of artificial primer mediated restriction sites to the selective amplification of mutant K-ras genes in stool samples from patients with colorectal carcinomas. In reconstitution experiments, down to 10 colorectal carcinoma cells could be detected in 100 mg of stool. For the diagnosis of micrometastatic disease, a sensitive and specific technique was established based on the reverse transcription of mRNA specific for the carcinoembryonic antigen followed by the amplification of the cDNA (RT-PCR). Attempts to establish a specific RT-PCR for cytokeratin-18 failed because of the existence of at least one processed pseudogene.
基于对突变肿瘤基因或组织特异性表达基因的选择性扩增,通过聚合酶链反应(PCR)可检测到从实体原发性肿瘤脱落的肿瘤细胞。当扩增肿瘤特异性改变时,与源自同一组织的正常细胞相比,可检测到少量肿瘤细胞。因此,可在胰液、粪便、尿液和痰液中特异性检测到恶性细胞。在此,我们描述了富集突变体PCR与引入人工引物介导的限制性酶切位点相结合,用于选择性扩增结直肠癌患者粪便样本中突变的K-ras基因。在重组实验中,在100mg粪便中可检测到低至10个结直肠癌细胞。为诊断微转移疾病,基于对癌胚抗原特异性mRNA的逆转录,随后扩增cDNA(RT-PCR),建立了一种灵敏且特异的技术。由于至少存在一个加工假基因,建立细胞角蛋白-18特异性RT-PCR的尝试失败了。